Exenatide-Linked GLP-1R PET/CT Trial Recruiting as of Sept 2026

A clinical trial update dated September 8, 2026 lists the study "Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease" as recruiting. The trial is registered under identifier NCT06725693 on ClinicalTrials.gov. No phase was specified in the available record. Exenatide is referenced in connection with GLP-1 receptor related research relevant to this study. The update states only the trial's title, recruitment status, and date. No results, efficacy data, or safety findings were included in this update. The trial's purpose, as named, involves imaging of the GLP-1 receptor using PET/CT technology in conditions related to GLP-1R. Recruiting status means the trial is currently enrolling participants but has not reported outcomes. Readers should note that a recruiting status reflects only that enrollment is underway, not any conclusions about the study's eventual findings. Further details on trial design, enrollment criteria, or endpoints were not included in the event data provided. Those interested in tracking this study can consult the official ClinicalTrials.gov listing for updates as the trial progresses. For background on exenatide itself, including its approved uses and general profile, readers can consult the compound overview.